Drugs / Bavdegalutamide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05177042 | May 2022 → Jul 2024 | metastatic prostate carcinoma | Arvinas Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03888612 | Mar 2019 → Apr 2024 | metastatic prostate carcinoma | Arvinas Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bavdegalutamide | “Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the...” PMID 39670468 ↗ Apr 2025 |
| Known as | ARV-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03888612 ↗ |
| Known as | ARV-110 (PROTAC) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4862963 ↗ |
| Modality | Small molecule | — CHEMBL4862963 ↗ |
| Route | Oral | “Part A: Oral tablet(s), once or twice daily in 28 day cycles” NCT03888612 ↗ |
| Target | AR | “Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the...” PMID 39670468 ↗ Apr 2025 |